Will Medpace Holdings, Inc. (MEDP) Go Down Anytime Soon?

The stock of Medpace Holdings, Inc. (NASDAQ:MEDP) is a huge mover today! The stock increased 4.25% or $3.48 during the last trading session, reaching $85.4. About 354,269 shares traded. Medpace Holdings, Inc. (NASDAQ:MEDP) has risen 67.33% since September 13, 2018 and is uptrending. It has outperformed by 67.33% the S&P500.
The move comes after 6 months positive chart setup for the $3.07B company. It was reported on Sep, 13 by Barchart.com. We have $88.82 PT which if reached, will make NASDAQ:MEDP worth $122.64M more.

Analysts await Medpace Holdings, Inc. (NASDAQ:MEDP) to report earnings on November, 4. They expect $0.71 EPS, up 5.97 % or $0.04 from last year’s $0.67 per share. MEDP’s profit will be $25.49M for 30.07 P/E if the $0.71 EPS becomes a reality. After $0.81 actual EPS reported by Medpace Holdings, Inc. for the previous quarter, Wall Street now forecasts -12.35 % negative EPS growth.

More notable recent Medpace Holdings, Inc. (NASDAQ:MEDP) news were published by: Finance.Yahoo.com which released: “Is Medpace Holdings, Inc. (MEDP) A Good Stock To Buy? – Yahoo Finance” on April 30, 2019, also Seekingalpha.com with their article: “Medpace Q1 2019 Earnings Preview – Seeking Alpha” published on April 28, 2019, Nasdaq.com published: “5 Small Cap Stocks With Growth AND Value – Nasdaq” on June 20, 2019. More interesting news about Medpace Holdings, Inc. (NASDAQ:MEDP) were released by: Bizjournals.com and their article: “One of Cincinnati’s largest private companies taps Medpace executive as CFO – Cincinnati Business Courier” published on April 26, 2019 as well as Bizjournals.com‘s news article titled: “Cincinnati health care firm joins S&P index – Cincinnati Business Courier” with publication date: December 24, 2018.

Medpace Holdings, Inc. provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company has market cap of $3.07 billion. The firm offers a suite of services supporting the clinical development process from Phase I to Phase IV in a range of therapeutic areas. It has a 36.22 P/E ratio. The Company’s services include medical affairs, clinical trial management, study feasibility, study start-up, clinical monitoring, global regulatory affairs, medical writing, biometrics, pharmacovigilance, core laboratory, and quality assurance.

Medpace Holdings, Inc. (NASDAQ:MEDP) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.